Cell-Based Assays_Revolutionizing Healthcare Without Animal Testing (A Market on the Rise).pptx

In a whirlwind of innovation, animal cell based testing service is set to embark on a meteoric rise, doubling its market share from USD 15.57 billion to an eye-watering USD 35.69 billion within the next eight years. At the heart of this transformative journey are cell-based assays (CBAs), heralded as the superheroes of healthcare innovation, swooping in to revolutionize traditional practices with their remarkable accuracy and ethical edge. The tiny Byomkesh Bakshis sleuthing within cells, uncovering clues about diseases, drug efficacy, and even crafting personalized therapies. With a dazzling compound annual growth rate (CAGR) of 8.7%, CBAs are not just a market trend but a seismic shift in healthcare dynamics. Fueling this exponential growth are factors like the surge in chronic diseases, the clamor for personalized medicine, and a tech renaissance propelling us towards a brighter medical future. Yet, amidst the glittering prospects, challenges loom like shadows in the night – from daunting startup costs to the scarcity of skilled hands and regulatory rigmaroles. Nevertheless, the future gleams with promise as technology leaps forward and government backing amplifies, paving the way for more accessible and widespread CBAs. Brace yourself for a paradigm shift where lab rats retire with a contented sigh, and precision medicine takes center stage, all thanks to the novel prowess of cell-based assays.

1. Cell-Based Assays: Revolutionizing Healthcare Without Animal Testing ( A Market on the Rise) Rajesh Kundapur Ph.D Faculty, DOS in Molecular Biology, University of Mysore, Karnataka-06

2. A market hotter than a Guntur chilli

3. The cell-based assays (CBAs) a revolutionary technology.

4. It's time to say, "Lab rats, have some chill."

5. tiny Byomkesh Bakshis’ investigating on cells for clues for ailments and effect of Drugs

6. USD 35.69 billion by 2032, up from USD 15.57 billion in 2022. Cell Based Assays

7. A compound annual growth rate (CAGR) of 8.7%

8. Rising prevalence of chronic diseases

9. Surging demand for personalized medicine

10. Rapid advancements in technology

11. Growing government support

12. North America currently dominates the market, In coming years Asia-Pacific will end up with silver medal.

13. Rising healthcare expenditure

14. Expanding healthcare infrastructure

15. Growing awareness of personalized medicine

16. So, the path a cake walk?..........., No challenges are there

17. High initial costs

18. Limited skilled personnel

19. Regulatory hurdles

20. The future of cell-based assays is bright.

21. Affordable and accessible CBAs

22. Increased adoption of CBAs in routine clinical practice

23. Personalized medicine becoming a reality for more patients

24. By replacing animal testing and offering superior accuracy and relevance, these assays are poised to revolutionize the way we understand diseases, develop drugs, and ultimately improve patient health.

25. Thanks for watching Rajesh Kundapur Ph.D